NATCOPHARM Intraday Analysis...

NATCOPHARM Share Price

Open 651.30 Change Price %
High 656.00 1 Day -4.20 -0.65
Low 645.00 1 Week 3.40 0.53
Close 646.25 1 Month 51.30 8.62
Volume 91810 1 Year 145.50 29.06
52 Week High 702.65
52 Week Low 390.00
NATCOPHARM Important Levels
Resistance 2 656.45
Resistance 1 652.25
Pivot 649.08
Support 1 640.26
Support 2 636.05
NSE INDIA Most Active Stocks
JPASSOCIAT 10.20 5.15%
SUZLON 15.70 0.64%
JINDALSTEL 80.20 3.48%
ADANIPOWER 37.85 2.30%
HINDALCO 177.00 3.48%
VEDL 244.40 3.52%
GMRINFRA 12.55 0.00%
BHEL 132.40 3.48%
POWERGRID 198.45 0.35%
NHPC 29.80 -0.50%
More..
NSE INDIA Top Gainers Stocks
RASOYPR 0.20 33.33%
FMNL 45.00 20.00%
INDOTHAI 25.05 19.86%
HOTELRUGBY 4.60 19.48%
OILCOUNTUB 52.05 17.89%
PANACEABIO 148.30 16.59%
ELGIRUBCO 55.95 15.96%
TRIL 437.90 15.42%
WEIZFOREX 244.90 14.81%
JINDCOT 16.85 14.63%
More..
NSE INDIA Top Losers Stocks
VKSPL 0.10 -33.33%
FCSSOFT 0.30 -14.29%
SPYL 1.00 -13.04%
NAKODA 0.40 -11.11%
UNITEDTEA 303.95 -8.55%
AGARIND 332.80 -7.14%
ASIL 0.70 -6.67%
CELESTIAL 21.30 -6.17%
KRIDHANINF 57.75 -6.02%
SUNDARAM 4.05 -5.81%
More..

Natco Pharma Limited (NSE: NATCOPHARM)

NATCOPHARM Technical Analysis 5
As on 18th Jan 2017 NATCOPHARM Share Price closed @ 646.25 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 555.77 & Strong Buy for SHORT-TERM with Stoploss of 604.59 we also expect STOCK to react on Following IMPORTANT LEVELS.
NATCOPHARM Target for January
1st Target up-side 615.05
2nd Target up-side 639.86
3rd Target up-side 664.67
1st Target down-side 544.25
2nd Target down-side 519.44
3rd Target down-side 494.63
NATCOPHARM Synopsis Technicals View
50 Day EMA N/A (Short Term)
N/A
100 Day EMA N/A (Mid Term) N/A
200 Day EMA N/A (Long Term) N/A
MACD (12 26 9) N/A N/A
RSI (14) N/A N/A
MFI (14) N/A N/A
CCI (20) N/A N/A
WILLIAM %R (14) N/A N/A
ADX (14) N/A N/A
PSAR N/A N/A
10 Day Avg Volume N/A
NATCOPHARM Other Details
Segment EQ
Market Capital 0.00
Sector Pharmaceuticals
Industry
Offical website
NATCOPHARM Address
NATCOPHARM
N/A
NATCOPHARM Latest News
Natco Pharma - Natco receives Generic Sofosbuvir (Sovaldi) approval for India   Moneycontrol.com   - 12th Mar 15
NATCO Pharma stock rises most on US court ruling   Business Today   - 11th Mar 15
Buy Natco Pharma; target of Rs 1920: ICICIdirect   Moneycontrol.com   - 11th Mar 15
UPDATE 1-India's Natco Pharma ties up with Gilead on hepatitis C drugs   Reuters   - 02nd Mar 15
Natco Pharma - Q3 results on Feb 11, 2015   Moneycontrol.com   - 30th Jan 15
Natco Pharma dips on preferential share allotment at discount   Business Standard   - 17th Dec 14
Natco Pharma CFO passes away   Hindu Business Line   - 23rd Oct 14
Gilead Sciences, Inc. v. Natco Pharma Ltd. (Fed. Cir.)   JD Supra (press release)   - 25th Jul 14
Gilead Sciences, Inc. v. Natco Pharma Limited   Lexology (registration)   - 08th May 14
Gilead Sciences, Inc. v. Natco Pharma Ltd. (Fed. Cir. 2014)   Patent Docs   - 29th Apr 14
Interactive Technical Analysis Chart Natco Pharma Limited ( NATCOPHARM NSE INDIA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Natco Pharma Limited
NATCOPHARM Business Profile
Natco Pharma is in the Pharmaceuticals sector. The current market capitalisation stands at Rs 2,439.26 crore.The company has reported a consolidated sales of Rs 179.22 crore and a Net Profit of Rs 24.26 crore for the quarter ended Sep 2013.The company management includes V C Nannapaneni - Chairman & Managing Director, Rajeev Nannapaneni - Vice Chairman & CEO, T V Rao - Nominee Director, G S Murthy - Director, B S Bajaj - Director, P Bhaskara Narayana - Director & CFO, A K S Bhujanga Rao - President & Director, Nitin Jagannath Deshmukh - Director. It is listed on the BSE with a BSE Code of 524816 and the NSE with an NSE Code of NATCOPHARM.Its Registered office is at NATCO House, Road No.2,,Banjara Hills Hyderabad,Andhra Pradesh - 500034.Their Registrars are Venture Capital & Corporate Investments Pvt. Ltd.